TEZSPIRE (tezepelumab) mechanism of action: blocking TSLP
Severe asthma involves several factors, so symptoms may stay hard to control even with treatment.
Airway walls can thicken and swell, leaving less space for air to move in and out.
Too much mucus can build up in the airways and clog them.
Triggers can release TSLP, which starts reactions linked with symptoms and flare-ups.
TEZSPIRE is designed to stop TSLP from working and may help make severe asthma easier to control.
Severe asthma can be hard to control, even when medicines are taken as prescribed. Airways can swell and narrow, mucus can build up, and muscle bands can tighten around the lungs. Triggers such as exercise, pollen, smoke, cold air, and chest infections can release TSLP, which starts reactions linked with symptoms and flare ups. TEZSPIRE is designed to stop TSLP from working. This may help stop severe asthma being triggered and make it easier to control.
The mechanism of action for TEZSPIRE in asthma has not been definitively established.
TEZSPIRE is a monoclonal antibody (IgG2λ) directed against thymic stromal lymphopoietin (TSLP)1, a key cytokine involved in initiating and perpetuating the inflammatory response in the airways. It plays a central role in activating various immune cells, contributing to the pathophysiology of asthma.1
TEZSPIRE prevents TSLP from binding to its heterodimeric receptor and disrupts this in the inflammatory cascade associated with asthma.1
Blocking TSLP with TEZSPIRE (tezepelumab) reduces a broad spectrum of biomarkers and cytokines associated with airway inflammation.1,2
How TEZSPIRE (tezepelumab) blocks TSLP in severe uncontrolled asthma
As an anti-TSLP monoclonal antibody, TEZSPIRE binds to TSLP upon its release by epithelial cells.1,2 TEZSPIRE’s mechanism of action in asthma has not been definitively established.
Adapted from Wechsler ME, et al. Respir Res. 2020.
The asthma triad
The diagnosis of asthma depends on objective measurements of variable airflow obstruction, airway hyperresponsiveness (AHR), and airway inflammation.3
Adapted from Nair P, et al. Clin Chest Med. 2012.
The primary endpoint of the CASCADE study was the change from baseline to week 28 in airway submucosal inflammatory cells (eosinophils, neutrophils, T cells, and mast cells) based on bronchoscopic biopsies.
Secondary endpoints assessed airway remodelling, changes in reticular basement membrane thickness, and epithelial integrity (proportions of damaged, denuded, and intact epithelium).
A selected exploratory endpoint examined changes in AHR to mannitol from baseline to the end of treatment (EOT), while an exploratory outcome evaluated changes in biomarkers and cytokines associated with airway inflammation over the same period.
As exploratory endpoints, the CASCADE trial also investigated the effect of TEZSPIRE on AHR and mucus plugging in patients with severe asthma.1,4,5,8,10-13
Why blocking TSLP is important in asthma treatment
TSLP is a cytokine produced in response to pro-inflammatory stimuli, playing a key role in the initiation and persistence of airway inflammation in asthma. Working at the epithelium, TSLP activates both innate and adaptive immune responses.4,5
It triggers both allergic/eosinophilic and non-allergic/eosinophilic inflammation, driving multiple downstream pathways implicated in clinical features of asthma13. By inhibiting TSLP, TEZSPIRE reduces a broad spectrum of biomarkers and cytokines associated with airway inflammation, including blood eosinophils (EOS), airway submucosal EOS, IgE, FeNO, IL-5, and IL-13.4,5,8,10
Through this mechanism of action, TEZSPIRE offers a first-in-class approach aimed at reducing underlying inflammation and improving asthma control.4
TEZSPIRE’S mechanism of action: phase II CASCADE, mechanistic study observations
The mechanisms by which TEZSPIRE improves clinical asthma outcomes were studied in the CASCADE phase II study. The trial's primary outcome measure was the reduction from baseline to the EOT in airway submucosal EOS. CASCADE found that this reduction was nominally significantly greater in patients treated with TEZSPIRE compared to those who received a placebo, ratio of geometric least squares mean (LSM) 0.15 (95% CI 0.05–0.41, p<0.001).10
This reduction is believed to result from its impact on airway mast cells and smooth muscle cells. Results are descriptive only. The clinical significance of this outcome and its impact on asthma have not been established.
In airway submucosal eosinophils.
There were no significant differences observed between treatment groups for changes in submucosal neutrophils, T cells or mast cells.10
One of the exploratory endpoints in the CASCADE trial was looking at the impact of airway hyperresponsiveness. Results are descriptive only. The clinical significance of this outcome and its impact on asthma have not been established.
EXPLORATORY ENDPOINT: AIRWAY HYPERRESPONSIVENESS8
PD is the provoking dose of mannitol that is required to cause a 15% decline in FEV1 from baseline. The higher the PD, the lower the airway hyperresponsiveness.
CASCADE (a phase 2, exploratory, mechanistic, 52-week, placebo-controlled trial, n=116) included patients with moderate-to-severe, uncontrolled asthma. All patients received SOC (MD or HD ICS + additional controller).10
Limitations: Patients were recruited to this trial mainly on the basis of treatment requirements and lung function measures, which did not translate into the expected baseline histological features. Because bronchoscopies for research purposes were not permitted during COVID-19 pandemic in countries where the study was conducted, for participants who could not visit the study site at Week 28 owing to the COVID-19 pandemic, treatment was extended to up to 52 weeks until they were able to visit the study site.10
The reduction in airway submucosal eosinophils with tezepelumab in this study was observed despite baseline submucosal eosinophil counts being lower than expected for patients with moderate-to-severe asthma.10
See efficacy data on how TEZSPIRE treats severe asthma phenotypes irrespective of key clinical biomarker levels.1,4,8
TEZSPIRE (tezepelumab) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment1
AHR, airway hyperresponsiveness; EOS, eosinophils; EOT, end of treatment; IgE, immunoglobulin E; IL-5, interleukin-5; IL-13, interleukin-13; FeNO, fractional exhaled nitric oxide; LSM, least squares mean; SOC, standard of care; TSLP, thymic stromal lymphopoietin.
Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020;21(1):264.
Nair P, Dasgupta A, Brightling CER, and Chung KF. How to diagnose and phenotype asthma. Clin Chest Med. 2012;33(3):445-457.
Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268.
Gauvreau Gail M., O’Byrne Paul M., Boulet Louis-Philippe, et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. N Engl J Med. 370(22):2102-2110.
Global Initiative for asthma. (GINA) Global Strategy for Asthma Management and Prevention. 2023. Available at ginasthma.org. (Last accessed December 2024).
Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. Immunity. 2019;50(4):975-991.
Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384(19):1800-1809.
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45-56.
Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377(10):936-946.
Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5).
Nordenmark L, Emson C, Hellqvist Å, et al. S46 Tezepelumab reduces mucus plugging in patients with uncontrolled, moderate-to-severe asthma: the phase 2 CASCADE study. Thorax. 2022;77(Suppl 1):A32-A32.
GB-60758 | DOP: November 2024
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
Cookies
We use cookies to provide website functionality, to analyze site usage, the content you visit and how you use it, to enable social media features and assist in our marketing efforts, including showing you personalized content. Only Necessary Cookies will be stored by default, and by clicking “Accept All”, you agree to the storage of all cookies on your device. You may personalize your preferences, obtain more information, and withdraw or change your consent at any time by clicking on “Set Preferences” or by visiting our Cookie Notice link available on the site. For more information about the use of cookies please see the cookie notice web page.
The strictly necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You may be able to decline these cookies through your browser, but necessary parts of the site will not then work. These cookies do not store any personally identifiable information.
Detailed description of cookies categorised as: Strictly Necessary Cookies.
Cookie
Expiry
Domain
Company
Purpose
wscrCookieConsent
30 days
www.myastrazeneca.co.uk
Digital Control Room Ltd
Your visit
Stores your cookie consent session for our site. It contains no information other than whether you have opted in or out for each cookie level.
Cookie that contains a session identifier used to authenticate the use and deliver different APIs. The cookie is dynamic so it cannot be updated, as each customer will have a unique cookie.
Cookie that contains a session identifier used to authenticate the use and deliver different APIs. The cookie is dynamic so it cannot be updated, as each customer will have a unique cookie.
These cookies enable the website to provide enhanced functionality, aid site personalisation, maintain user-selected options and site navigation aids. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Detailed description of cookies categorised as: Functional Cookies.
Cookie
Expiry
Domain
Company
Purpose
popupShown
Session
www.myastrazeneca.co.uk
AstraZeneca
User preferences
New pop up to support the Trixeo NGP launch and clearly sign post new material on offer.
New pop up to support the Trixeo NGP launch and clearly sign post new material on offer.
These cookies allow us to count visits and traffic sources, perform customer surveys and other web analytics, so we can measure and improve the performance of our site. They help us know which pages are the most and least popular and see how visitors move around the site. The information these cookies collect is aggregated and in some instances limited identifiable data may be collected.
Detailed description of cookies categorised as: Performance and Operational Cookies.
Cookie
Expiry
Domain
Company
Purpose
everest_g_v2
2 years
everesttech.net
Adobe Inc.
Analytics
These cookies provide feedback on the effectiveness of the advertising displayed on our site and helps show you offers which may be of interest to you.
These cookies provide feedback on the effectiveness of the advertising displayed on our site and helps show you offers which may be of interest to you.
These cookies provide feedback on the effectiveness of the advertising displayed on our site and helps show you offers which may be of interest to you.
These cookies provide feedback on the effectiveness of the advertising displayed on our site and helps show you offers which may be of interest to you.
Measure website traffic via anonymous statistics. Among other things, which links users click on and where they most often move the mouse, so that we can optimize the user experience on our website.
Measure website traffic via anonymous statistics. Among other things, which links users click on and where they most often move the mouse, so that we can optimize the user experience on our website.
Measure website traffic via anonymous statistics. Among other things, which links users click on and where they most often move the mouse, so that we can optimize the user experience on our website.
Measure website traffic via anonymous statistics. Among other things, which links users click on and where they most often move the mouse, so that we can optimize the user experience on our website.
These cookies allow us to count visits and traffic sources, perform customer surveys and other web analytics, so we can measure and improve the performance of our site. They help us know which pages are the most and least popular and see how visitors move around the site. The information these cookies collect is aggregated and in some instances limited identifiable data may be collected.
These cookies allow us to count visits and traffic sources, perform customer surveys and other web analytics, so we can measure and improve the performance of our site. They help us know which pages are the most and least popular and see how visitors move around the site. The information these cookies collect is aggregated and in some instances limited identifiable data may be collected.
Manages user session for site functionality, expiring when browser closes.
Manages user session for site functionality, expiring when browser closes.
im_cookie_visitor_uid
27 years, 4 months
myastrazeneca.co.uk
Adobe, Adobe Inc.
Analytics
Tracks visitor behaviour across multiple sessions to improve user experience, with a long-term expiry.
Tracks visitor behaviour across multiple sessions to improve user experience, with a long-term expiry.
AMCVS_*AdobeOrg
Session
myastrazeneca.co.uk
Adobe Analytics, Adobe Inc.
Analytics
Session cookie with Adobe. It indicates that a session has been initialized. The organisation ID helps Adobe to only analyse traffic from legitimate websites.
Session cookie with Adobe. It indicates that a session has been initialized. The organisation ID helps Adobe to only analyse traffic from legitimate websites.
This cookie is set and read by the Adobe Analytics JavaScript code when the page is loaded. Captures Adobe Analytics page name. No Personally Identifiable Information collected.
This cookie is set and read by the Adobe Analytics JavaScript code when the page is loaded. Captures Adobe Analytics page name. No Personally Identifiable Information collected.
demdex
2 years
demdex.net
Adobe Media Optimizer, Adobe Inc.
Analytics
Used to recognize a returning visitor, build unique audience profiles and deliver targeted messages using Adobe Analytics.
Used to help Adobe Audience Manager perform basic functions such as visitor identification, ID synchronization, segmentation, modelling, reporting, etc
Used to help Adobe Audience Manager perform basic functions such as visitor identification, ID synchronization, segmentation, modelling, reporting, etc
Collects anonymous data and determines what advertising has been delivered to the user already, on behalf of Advertising platform Flashtalking by Simplicity Marketing Ltd.
Collects anonymous data and determines what advertising has been delivered to the user already, on behalf of Advertising platform Flashtalking by Simplicity Marketing Ltd.
These cookies are used to track our visitors browsing habits and activity across our websites. They can be used to build up a profile of search and/or browsing history for every visitor. Identifiable or unique data may be collected which enables us to show you relevant/personalized marketing content. We do not store directly personal information, but information that uniquely identify your browser and internet device and use this to display targeted advertising and/or share this data with third parties for the same purpose. If you do not allow these cookies, you will experience less personalized marketing content and targeted advertising.
We do not use any cookies in this category.
What are cookies, how are they used and how are they managed?
Cookies are small text files that contain letters and numbers and are placed on your computer or device. Cookies are set when you visit a website that uses cookies and may be used to keep track of pages visited within the site, help you continue where you left off or remember your preferences, such as language settings.
Cookies are very important to help us make online services easier to use, to monitor the use of our site and to help us improve the service to you.
To make it easier for you to understand the way a website uses cookies, we have grouped them into easy to understand categories. The category to which a cookie belongs can be seen in the Cookie Panel.
The information in the Cookie Panel is provided to you in an open and transparent way, so that you can see how cookies are used to enrich your visitor experience and make an informed choice to allow their usage. However, if you wish to control and remove cookies, this can be done via settings in your web browser.
Please be aware that restricting cookies may impact the functionality of a website. Many of the interactive functions offered by websites are dependent on cookies and disabling or blocking cookies can prevent these services from working or reduce their usefulness.
Different web browsers may use different methods for managing cookies. Please follow the instructions below, from the web browser manufacturers directly, to configure your browser settings*.